How TB006 at Universal Neurological Care Offers Hope for Alzheimer's Patients

Universal Neurological Care offers TB006, an investigational drug being evaluated for Alzheimer’s disease, to eligible patients through the Expanded Access Program (EAP), a program authorized by the FDA.

About TB006

TB006 is an investigational drug developed by TrueBinding. In clinical trials, TB006 is currently being evaluated for its potential effects on memory and cognition. TrueBinding’s Phase 2b trial is expected to begin in early 2027. TB006 is experimental and still undergoing clinical testing, and it is not yet FDA approved. Its safety and effectiveness have not been established.

What to Expect at a Screening Consultation

Interested patients or caregivers can contact us to schedule a screening consultation. Our team will:

• evaluate eligibility
• perform a history and physical exam, including an EKG and an SNP genetic test
• discuss the risks and benefits of participation
• submit the requisite orders for lab and imaging testing
• submit your application to the drug sponsor for approval

To learn more, visit our TB006 page or call Universal Neurological Care at (904) 404-7044 to schedule a consultation with Dr. Asad.